IL21R

Across TCGA pan-cancer cohorts, IL21R Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IL21R data layer compared with 24 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher IL21R Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL21R expression acts as an unfavorable survival marker.

BRCA, HNSC, and LGG are the cancer types where IL21R Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.126	0.579	<.001	20	view →
HNSC	DFS	Median	IV	0.128	0.669	.011	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
BLCA	OS	Median	III,IV	0.216	0.581	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IL21R–BRCA (OS)

Open the BRCA breakdown →